Transition From Distinct Types of KRAS Mutation-Harboring Multifocal Lung Adenocarcinoma to Rhabdoid Tumor: A Longitudinal Follow-Up

Kensuke Setoguchi; Shigehisa Yanagi; Toshihiro Gi; Hironobu Tsubouchi; Kazuko Uto; Takafumi Shigekusa; Nobuhiro Matsumoto; Yuichiro Sato; Masamitsu Nakazato

doi:10.12659/AJCR.932452

25 August 2021: Articles

Transition From Distinct Types of Mutation-Harboring Multifocal Lung Adenocarcinoma to Rhabdoid Tumor: A Longitudinal Follow-Up

Challenging differential diagnosis, Rare disease

Kensuke Setoguchi ^* , Shigehisa Yanagi ^** , Toshihiro Gi ^A , Hironobu Tsubouchi ^A , Kazuko Uto ^A , Takafumi Shigekusa ^A , Nobuhiro Matsumoto ^A , Yuichiro Sato ^A , Masamitsu Nakazato ^A

DOI: 10.12659/AJCR.932452

Am J Case Rep 2021; 22:e932452

Authors information Article notes Copyright and License information

Background Case Report Discussion Conclusions References:

View HTML version

No.	Author, Year	Rhabdoid cells (%)	Associated tumor type	Driver mutation	Follow-up (months)	Vital status	Ref.
1	Cavazza et al 1996	90	LCC	NA	6	Alive	[]⁵
2		>10	Sarcoma	NA	4	Alive	[]⁵
3		>10	Ad	NA	4	Dead	[]⁵
4		10	Ad	NA	2	Alive	[]⁵
5		>10	LCC	NA	5	Alive	[]⁵
6		10	LCC	NA	NA	NA	[]⁵
7	Rubenchik et al 1996	Most	NA	NA	24	Alive	[]¹⁵
8	Chetty et al 1997	>10	Ad	NA	6	Dead	[]¹⁶
9		25	LCNEC	NA	3	Dead	[]¹⁶
10		>10	Ad	NA	6	NA	[]¹⁶
11	Chetty 2000	15	LCNEC, SCC	NA	6	Dead	[]¹⁷
12		10	LCNEC, SCC, SqCC	NA	12	Dead	[]¹⁷
13	Miyagi et al 2000	70	Ad	NA	36	Dead	[]¹⁸
14		90	Ad	NA	4	Dead	[]¹⁸
15		50	Ad	NA	41	Alive	[]¹⁸
16	Shimazaki et al 2001	18.2	PDUT	NA	1.5	Dead	[]⁶
17		15.5	PDUT	NA	0.6	Dead	[]⁶
18		15	PDUT	NA	1	Dead	[]⁶
19		60	PDUT	NA	10	Dead	[]⁶
20	Attems et al 2001	NA	PMAC	NA	3	Dead	[]¹⁹
21	Kaneko et al 2002	90	LCC	NA	63	Alive	[]²⁰
22	Hiroshima et al 2003	Most	LCC	NA	72	Alive	[]²¹
23	Tamboli et al 2004	25	SarC	NA	NA	LFU	[]²²
24		90	LCC	NA	11	Dead	[]²²
25		15	LCC	NA	4	Dead	[]²²
26		10	Ad	NA	19	Dead	[]²²
27		90	LCC	NA	5	Dead	[]²²
28		90	Ad	NA	10	Dead	[]²²
29		30	SarC	NA	15	Dead	[]²²
30		50	Ad	NA	3	Dead	[]²²
31		60	SarC	NA	3	Dead	[]²²
32		75	SarC	NA	NA	LFU	[]²²
33		20	Ad	NA	20	Alive	[]²²
34	Yilmazbayhan et al 2005	100	LCC	NA	2	Dead	[]²³
35	Falconieri et al 2005	100	ERC	NA	NA	Alive	[]²⁴
36		100	ERC	NA	NA	Alive	[]²⁴
37		100	ERC	NA	NA	LFU	[]²⁴
38		100	ERC	NA	NA	Dead	[]²⁴
39	Goto et al 2006	Most	LCC	NA	6	Dead	[]²⁵
40	Song et al 2007	30	IMA	NA	NA	Alive	[]²⁶
41	Saini et al 2009	Most	LCC	NA	57	Alive	[]²⁷
42	Izquierdo-Garcia 2010	30	Ad	NA	15	Dead	[]²⁸
43		80	Pleomorphic	NA	6	Dead	[]²⁸
44		50	Ad	NA	2	Dead	[]²⁸
45		10	SqCC	NA	31	Dead	[]²⁸
46		80	LCC	NA	123	Alive	[]²⁸
47		10	LCC	NA	23	Dead	[]²⁸
48		40	Ad	NA	6	Dead	[]²⁸
49	Otera 2010	80	PDUT		1	Dead	[]²⁹
50	Attia 2011	NA	NA	NA	NA	NA	[]³⁰
51	Dettmer 2012	90	Ad	EGFR exon19 deletion	8	Alive	[]³¹
52	Kim 2014	Most	NA	NA	NA	Alive	[]³²
53	Bahadur 2015	10	LCC	NA	NA	Alive	[]³³
54	Zysman 2016	NA	NA	NA	3	Dead	[]³⁴
Ad – adenocarcinoma; AG – adrenal gland; AIS – adenocarcinoma in situ; EGFR – epithelial growth factor receptor; ERC – exclusive rhabdoid carcinoma; IMA – invasive mucinous adenocarcinoma; LCC – large-cell carcinoma; LCNEC – large-cell neuroendocrine carcinoma; LN – lymph node; NA – not available; PDUT – poorly differentiated or undifferentiated tumor; Peric – pericardial; PMAC – pseudomesotheliomatous adenocarcinoma; SarC – sarcomatoid carcinoma; SCC – small-cell carcinoma; SqCC – squamous cell carcinoma.

Back to the Article

Transition From Distinct Types of Mutation-Harboring Multifocal Lung Adenocarcinoma to Rhabdoid Tumor: A Longitudinal Follow-Up

Your Privacy